BACKGROUND: Inflammation has been identified as a hallmark of high-risk Group A (GpA) ependymoma (EPN). Chronic interleukin (IL)-6 secretion from GpA tumors drives an immune suppressive phenotype by polarizing infiltrating monocytes. This study determines the mechanism by which IL-6 is dysregulated in GpA EPN. METHODS: Twenty pediatric GpA and 21 pediatric Group B (GpB) EPN had gene set enrichment analysis for MSigDB Hallmark gene sets performed. Protein and RNA from patients and cell lines were used to validate transcriptomic findings. GpA cell lines 811 and 928 were used for in vitro experiments performed in this study. RESULTS: The nuclear factor-kappaB (NF-κB) pathway is a master regulator of IL-6 and a signaling pathway enriched in GpA compared with GpB EPN. Knockdown of NF-κB led to significant downregulation of IL-6 in 811 and 928. NF-κB activation was independent of tumor necrosis factor alpha (TNF-α) stimulation in both cell lines, suggesting that NF-κB hyperactivation is mediated through an alternative mechanism. Leucine zipper downregulated in cancer 1 (LDOC1) is a known transcriptional repressor of NF-κB. In many cancers, LDOC1 promoter is methylated, which inhibits gene transcription. We found decreased LDOC1 gene expression in GpA compared with GpB EPN, and in other pediatric brain tumors. EPN cells treated with 5AZA-DC, demethylated LDOC1 regulatory regions, upregulated LDOC1 expression, and concomitantly decreased IL-6 secretion. Stable knockdown of LDOC1 in EPN cell lines resulted in a significant increase in gene transcription of v-rel avian reticuloendotheliosis viral oncogene homolog A, which correlated to an increase in NF-κB target genes. CONCLUSION: These results suggest that epigenetic silencing of LDOC1 in GpA EPN regulates tumor biology and drives inflammatory immune phenotype.
BACKGROUND: Inflammation has been identified as a hallmark of high-risk Group A (GpA) ependymoma (EPN). Chronic interleukin (IL)-6 secretion from GpA tumors drives an immune suppressive phenotype by polarizing infiltrating monocytes. This study determines the mechanism by which IL-6 is dysregulated in GpA EPN. METHODS: Twenty pediatric GpA and 21 pediatric Group B (GpB) EPN had gene set enrichment analysis for MSigDB Hallmark gene sets performed. Protein and RNA from patients and cell lines were used to validate transcriptomic findings. GpA cell lines 811 and 928 were used for in vitro experiments performed in this study. RESULTS: The nuclear factor-kappaB (NF-κB) pathway is a master regulator of IL-6 and a signaling pathway enriched in GpA compared with GpB EPN. Knockdown of NF-κB led to significant downregulation of IL-6 in 811 and 928. NF-κB activation was independent of tumor necrosis factor alpha (TNF-α) stimulation in both cell lines, suggesting that NF-κB hyperactivation is mediated through an alternative mechanism. Leucine zipper downregulated in cancer 1 (LDOC1) is a known transcriptional repressor of NF-κB. In many cancers, LDOC1 promoter is methylated, which inhibits gene transcription. We found decreased LDOC1 gene expression in GpA compared with GpB EPN, and in other pediatric brain tumors. EPN cells treated with 5AZA-DC, demethylated LDOC1 regulatory regions, upregulated LDOC1 expression, and concomitantly decreased IL-6 secretion. Stable knockdown of LDOC1 in EPN cell lines resulted in a significant increase in gene transcription of v-rel avian reticuloendotheliosis viral oncogene homolog A, which correlated to an increase in NF-κB target genes. CONCLUSION: These results suggest that epigenetic silencing of LDOC1 in GpA EPN regulates tumor biology and drives inflammatory immune phenotype.
Authors: Michelle Monje; Siddhartha S Mitra; Morgan E Freret; Tal B Raveh; James Kim; Marilyn Masek; Joanne L Attema; Gordon Li; Terri Haddix; Michael S B Edwards; Paul G Fisher; Irving L Weissman; David H Rowitch; Hannes Vogel; Albert J Wong; Philip A Beachy Journal: Proc Natl Acad Sci U S A Date: 2011-03-01 Impact factor: 11.205
Authors: Hatice Duzkale; Carmen D Schweighofer; Kevin R Coombes; Lynn L Barron; Alessandra Ferrajoli; Susan O'Brien; William G Wierda; John Pfeifer; Tadeusz Majewski; Bogdan A Czerniak; Jeffrey L Jorgensen; L Jeffrey Medeiros; Emil J Freireich; Michael J Keating; Lynne V Abruzzo Journal: Blood Date: 2011-02-10 Impact factor: 22.113
Authors: Andrea M Griesinger; Rebecca J Josephson; Andrew M Donson; Jean M Mulcahy Levy; Vladimir Amani; Diane K Birks; Lindsey M Hoffman; Steffanie L Furtek; Phillip Reigan; Michael H Handler; Rajeev Vibhakar; Nicholas K Foreman Journal: Cancer Immunol Res Date: 2015-05-12 Impact factor: 11.151
Authors: Hendrik Witt; Stephen C Mack; Marina Ryzhova; Sebastian Bender; Martin Sill; Ruth Isserlin; Axel Benner; Thomas Hielscher; Till Milde; Marc Remke; David T W Jones; Paul A Northcott; Livia Garzia; Kelsey C Bertrand; Andrea Wittmann; Yuan Yao; Stephen S Roberts; Luca Massimi; Tim Van Meter; William A Weiss; Nalin Gupta; Wiesia Grajkowska; Boleslaw Lach; Yoon-Jae Cho; Andreas von Deimling; Andreas E Kulozik; Olaf Witt; Gary D Bader; Cynthia E Hawkins; Uri Tabori; Abhijit Guha; James T Rutka; Peter Lichter; Andrey Korshunov; Michael D Taylor; Stefan M Pfister Journal: Cancer Cell Date: 2011-08-16 Impact factor: 31.743
Authors: Khalida Wani; Terri S Armstrong; Elizabeth Vera-Bolanos; Aditya Raghunathan; David Ellison; Richard Gilbertson; Brian Vaillant; Stewart Goldman; Roger J Packer; Maryam Fouladi; Ian Pollack; Tom Mikkelsen; Michael Prados; Antonio Omuro; Riccardo Soffietti; Alicia Ledoux; Charmaine Wilson; Lihong Long; Mark R Gilbert; Ken Aldape Journal: Acta Neuropathol Date: 2012-02-10 Impact factor: 17.088
Authors: Lee Ridley; Ruman Rahman; Marie-Anne Brundler; David Ellison; James Lowe; Keith Robson; Emma Prebble; Inga Luckett; Richard J Gilbertson; Sheila Parkes; Vikki Rand; Beth Coyle; Richard G Grundy Journal: Neuro Oncol Date: 2008-08-13 Impact factor: 12.300
Authors: Davis A Witt; Andrew M Donson; Vladimir Amani; Daniel C Moreira; Bridget Sanford; Lindsey M Hoffman; Michael H Handler; Jean M Mulcahy Levy; Kenneth L Jones; Anandani Nellan; Nicholas K Foreman; Andrea M Griesinger Journal: Pediatr Blood Cancer Date: 2018-01-19 Impact factor: 3.167
Authors: Angela M Pierce; Davis A Witt; Andrew M Donson; Ahmed Gilani; Bridget Sanford; Martin Sill; Benjamin Van Court; Ayman Oweida; Eric W Prince; Jenna Steiner; Etienne Danis; Kathleen Dorris; Todd Hankinson; Michael H Handler; Kenneth L Jones; Sana D Karam; Natalie J Serkova; Rajeev Vibhakar; Nicholas K Foreman; Andrea M Griesinger Journal: Neuro Oncol Date: 2019-12-17 Impact factor: 12.300
Authors: Rachael G Aubin; Emma C Troisi; Javier Montelongo; Adam N Alghalith; Maclean P Nasrallah; Mariarita Santi; Pablo G Camara Journal: Nat Commun Date: 2022-07-08 Impact factor: 17.694
Authors: Amr H Saleh; Nardin Samuel; Kyle Juraschka; Mohammad H Saleh; Michael D Taylor; Michael G Fehlings Journal: Nat Rev Cancer Date: 2022-01-14 Impact factor: 69.800
Authors: Austin E Gillen; Kent A Riemondy; Vladimir Amani; Andrea M Griesinger; Ahmed Gilani; Sujatha Venkataraman; Krishna Madhavan; Eric Prince; Bridget Sanford; Todd C Hankinson; Michael H Handler; Rajeev Vibhakar; Ken L Jones; Siddhartha Mitra; Jay R Hesselberth; Nicholas K Foreman; Andrew M Donson Journal: Cell Rep Date: 2020-08-11 Impact factor: 9.423
Authors: Shiqi Zhang; Tao Zeng; Bin Hu; Yu-Hang Zhang; Kaiyan Feng; Lei Chen; Zhibin Niu; Jianhao Li; Tao Huang; Yu-Dong Cai Journal: Front Bioeng Biotechnol Date: 2020-05-26
Authors: Ming Zhang; Rajiv R Iyer; Tej D Azad; Qing Wang; Tomas Garzon-Muvdi; Joanna Wang; Ann Liu; Peter Burger; Charles Eberhart; Fausto J Rodriguez; Daniel M Sciubba; Jean-Paul Wolinsky; Ziya Gokaslan; Mari L Groves; George I Jallo; Chetan Bettegowda Journal: Sci Rep Date: 2019-12-10 Impact factor: 4.379